Search results
Clovis Oncology Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. via Yahoo Finance· 2 years agoClovis Oncology (NASDAQ:CLVS) Third Quarter 2022 ResultsKey Financial Results Revenue: US$30.7m...
The Clovis Oncology, Inc. (NASDAQ:CLVS) Analysts Have Been Trimming Their Sales Forecasts
Simply Wall St. via Yahoo Finance· 2 years agoToday is shaping up negative for Clovis Oncology, Inc. (NASDAQ:CLVS) shareholders, with the analysts...
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) delivered earnings and revenue surprises of 7.14% and 11.87%, respectively, for the...
Why Clovis Oncology Zoomed 30% Higher Today
Motley Fool· 2 years agoCancer-focused biotech Clovis Oncology (NASDAQ: CLVS) was a stock on fire Monday. On Sunday, Clovis reported that Rubraca tested very well as a...
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings...
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why
Zacks via Yahoo Finance· 2 years agoClovis Oncology, Inc.’s CLVS shares have plunged 49.6% in the past six months against the industry’s...
Zacks.com featured highlights include Clovis Oncology, NiSource, DocuSign, Root and Endava
Zacks via Yahoo Finance· 2 years agoFor Immediate Release Chicago, IL – December 22, 2022 – Stocks in this week’s article are Clovis...
Clovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing Looms
Benzinga via Yahoo Finance· 2 years agoClovis Oncology Inc (NASDAQ: CLVS) posted a Q3 EPS loss of $(0.39), up from $(0.56) a year ago, on...
Cancer Focused Clovis Oncology Files For Bankruptcy
Benzinga via Yahoo Finance· 2 years agoClovis Oncology Inc (NASDAQ: CLVS) has voluntarily initiated a Chapter 11 proceeding in the U.S. Bankruptcy Court and will seek to sell its assets...
Clovis Oncology's Flagship Ovarian Cancer Drug Improves Progression-Free Survival As First-Line...
Benzinga via Yahoo Finance· 2 years agoClovis Oncology Inc (NASDAQ: CLVS) announced results from a subgroup analysis from the Phase 3...